Lotus Eye Hospital & Institute Q2 Results 2026: PAT ₹0 Cr
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹18Cr
- Net profit
- ₹0Cr
- Margin
- 14.4%
Top 10 Healthcare Services companies on management guidance
See the sector's top 10 — free with your mobile number.
Lotus Eye Hospital & Institute Ltd Q2 FY27 key numbers
- Revenue
- Total income (including other income) for the quarter was Rs. 1,797.14 lakhs versus Rs. 1,330.93 lakhs in the prior year quarter.
As stated in Lotus Eye Hospital & Institute Ltd's Q2 FY27 results statement · published 11 Nov 2026. Reported figures, not investment advice.
Based on Lotus Eye Hospital & Institute Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the quarter ended September 30, 2026, was Rs. 1,772.41 lakhs, compared to Rs. 1,303.84 lakhs for the quarter ended September 30, 2025, indicating a year-on-year increase of. Quarterly EBITDA: Rs. 267 million, up 33.6% YoY (Rs. 200 million same quarter last year).
From Lotus Eye Hospital & Institute Ltd's Q2 FY27 earnings-call transcript · updated 11 Nov 2026.
How did Lotus Eye Hospital & Institute's revenue grow in the September 2026 quarter?
- Revenue from operations for the quarter ended September 30, 2026, was Rs. 1,772.41 lakhs, compared to Rs. 1,303.84 lakhs for the quarter ended September 30, 2025, indicating a year-on-year increase of approximately 36%.
- Total income (including other income) for the quarter was Rs. 1,797.14 lakhs versus Rs. 1,330.93 lakhs in the prior year quarter.
What happened to Lotus Eye Hospital & Institute's margins in Q2 FY27?
See what Lotus Eye Hospital & Institute Ltd said on profitability & margins — free account, 30 seconds.
What capex is Lotus Eye Hospital & Institute planning?
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Lotus Eye Hospital & Institute raising money or cutting debt?
See what Lotus Eye Hospital & Institute Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Lotus Eye Hospital & Institute's order book?
See what Lotus Eye Hospital & Institute Ltd said on order book & pipeline — free account, 30 seconds.
Lotus Eye Hospital & Institute Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.
Lotus Eye Hospital & Institute Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 18 |
| Operating profit (EBITDA) | 3 |
| Operating margin | 14.4% |
| Profit before tax | 1 |
| Net profit (PAT) | 0 |
| EPS (₹) | 0.21 |
Source: Lotus Eye Hospital & Institute Ltd's results filing to NSE (standalone), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹17 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Healthcare Services
Continue your research
Others in Healthcare Services this season
- Nidan Laboratories & Healthcare (Q2 FY27)
Operating Margin: Not explicitly stated as a percentage; however, total income from operations is Rs 1,201.76 lakhs, so approximate operating margin = (EBITDA…
- Suven Life Sciences (Q2 FY27)
91.92 lakhs for the quarter ended September 30, 2025, indicating a revenue increase of approximately 30.3%. Key results statement takeaways from Suven Life Scie
- Aster DM Quality (Q2 FY27)
Q2 FY27 revenue: INR 2,829 Cr, up 19% YoY from INR 2,382 Cr in Q2 FY26 (Page 6, 9, 10). Key investor presentation takeaways from Aster DM Quality Care Ltd's Q2
- Fortis Healthcare (Q2 FY27)
Patient volume in diagnostics grew 5.8% YoY in Q2 and 9.9% quarter-on-quarter, with test volume growth at 7.2% YoY. Key concall takeaways from Fortis…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM QualityGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Lotus Eye Hospital & Institute Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Lotus Eye Hospital & Institute Ltd Q2 FY27 results?
Revenue from operations for the quarter ended September 30, 2026, was Rs. 1,772.41 lakhs, compared to Rs. 1,303.84 lakhs for the quarter ended September 30, 2025, indicating a year-on-year increase of. Quarterly EBITDA: Rs. 267 million, up 33.6% YoY (Rs. 200 million same quarter last year).
What is Lotus Eye Hospital & Institute Ltd share price analysis?
Lotus Eye Hospital & Institute Ltd currently shows a neutral. The stock trades at a P/E of 1349.1 with a market cap of ₹216 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Lotus Eye Hospital & Institute Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.